Available Technologies by Category
Antigen-specific Cell Programming Using non-viral Approaches
  • This innovative technology uses synthetic nanoparticles to deliver gene modulators and engineered MHC molecules directly to antigen-specific T cells in vivo, enhancing T cell functions and bypassing ex vivo processes.
  • The prototype improves T cell specificity and reduces off-target toxicity, significantly lowering costs and manufacturing time for effective T cell therapies.
  • It has applications in cancer therapy, immune therapy, autoimmune disease therapy, and infectious disease therapy.
8703
Scarless isolation of antigen-specific T cells for CAR T cell manufacturing via DNA-gated sorting
  • This technology introduces DNA-gated sorting (DGS) for label-free isolation of antigen-specific CD8+ T cells, improving CAR T cell therapy.
  • The prototype enhances CAR T cell scalability and therapeutic effectiveness against solid tumors by using a DNA gate mechanism for targeted T cell capture and release.
  • DGS improves in vivo persistence and specificity of CAR T cells, offering better treatment outcomes for solid tumors and other cancers.
9388
Needle-like Nanostructures to Deliver Multi-scale Biomolecules to Non-activated Immune Cells
  • This functionalized nanowire platform delivers multiple genetic materials to naïve T and B cells without pre-activation, enhancing their efficacy in adoptive cell therapy.
  • The prototype improves gene delivery efficiency while preserving the naïve state of immune cells, increasing cell viability and immune response modulation.
  • It offers superior protection against intracellular pathogens and serves as a research tool for immune cell manipulation across various species, ages, and subtypes.
9431
Multi-Niche Human Bone Marrow-On-A-Chip for Plasma Cell Survival and Differentiation
  • This novel microfluidic chip simulates the human bone marrow environment, incorporating multiple niches and supporting long-term plasma cell culture and study.
  • The prototype enables comprehensive study of plasma cell maturation, aiding the development of targeted therapies for plasma cell-related disorders.
  • It overcomes limitations in traditional plasma cell culture, facilitating vaccine development, antibody production research, and immune response modulation.
9246
Lymphoid-Lymphatics-Integrated Organ-on-Chip Device and Method
  • This innovative organ-on-chip system combines vascularized lung and lymphoid tissues, aiding studies on airway infections.
  • The prototype supports diverse cell cultures, making it useful for screening treatments and vaccines.
  • It enhances current lung-on-chip models by accurately simulating lung tissue and immune responses.
9349
An Electronic Microfluidic Platform for On-Chip Apoptosis Quantification using Annexin V-Based PS Externalization Detection-GT NEXT
  • This electronic microchip integrates an electrical sensor network with a microfluidic capture chamber to detect phosphatidylserine (PS) externalization, offering a compact, user-friendly, and cost-effective solution for apoptotic analysis.
  • The prototype provides high sensitivity and specificity without the need for prelabeling, making it suitable for diverse applications in clinical diagnostics and biomedical research.
  • It supports drug discovery, toxicity evaluation, and bioprocessing optimizations, enhancing disease mechanism studies and therapeutic target identification.
9306
Capillary Driven Microneedle Patch for Blood Biomarker Analysis
  • This bioresorbable thermoplastic microneedle platform accurately collects capillary blood and quantifies biomarkers on-chip, supported by a smartphone attachment for easy read-out.
  • The prototype integrates hollow microneedles with microfluidic patterns and crossflow filtration, providing low-cost, reliable, and sensitive point-of-care blood testing.
  • It enables point-of-care personalized diagnostics and blood biomarker analysis in clinical and remote settings without expensive peripheral equipment.
9292
Functionalized Nanowires for miRNA-mediated Programming of Naive T Cells
  • Technology Overview: Georgia Tech's functionalized nanowires deliver genetic materials like miRNAs and CRISPR directly to naive T cells, enhancing their therapeutic potential without pre-activation.
  • Advantages: This method preserves the naive state of T cells, allowing for better viability and functionality, reduced exhaustion, and delivery of both small and large biomolecules, including lentiviral particles.
  • Commercial Applications: The technology can be used in adoptive T cell therapy for cancer and infectious diseases, therapeutic delivery of biomolecules, and as a research tool for immune cell manipulation.
9341
Lymphoid Tissues with Switchable Protein Gradients
  • Technology Overview: Georgia Tech's hydrogel-based immune organoids mimic lymphoid tissue, enabling ex vivo differentiation of B cells and studying immune responses to infections and vaccinations.
  • Advantages: This non-invasive method supports long-term B and T cell survival, mimics antibody production processes, and offers insights into diseases like lymphoma.
  • Commercial Applications: Useful for drug discovery, clinical research on immune disorders, personalized medicine, and academic studies in immunology.
2024-116
Engineering Antigen-Specific T Cells for CAR T Cell Therapy via Antigen-Presenting Lipid Nanoparticles
  • Technology Overview: Georgia Tech's new CAR T cell therapy uses lipid nanoparticles (LNPs) to program antigen-specific T cells in vivo, potentially reducing costs and production time.

  • Advantages: This approach avoids expensive and time-consuming ex vivo manufacturing, minimizes off-target effects, can adapt to various CAR constructs and cancer types, and promises rapid scaling and reduced costs.

  • Commercial Applications: Applicable to multiple myeloma, CD19+ cancers, and a wide range of other cancers, this technology streamlines CAR T cell therapy manufacturing for faster, more affordable treatments.

9386
Driving Neural Activity to Rapidly Control Inflammation, Protein, and Gene Expression in the Brain
  • Novel non-invasive method utilizing neural activity to swiftly control inflammation, protein, and gene expression in the brain.
  • The technology enables rapid and precise modulation of brain functions, potentially revolutionizing treatment for various neurological conditions.
  • Commercial applications include treating Alzheimer's, schizophrenia, autism, epilepsy, and more, offering faster, non-invasive, and targeted therapeutic options.
7773
Novel Hydrogels for Encapsulation, Vascularization, and Transplantation of Cells
  • This hydrolytically degradable poly(ethylene glycol) (PEG) hydrogel leverages ester linkages combined at various ratios with non-degradable macromers to enable tunable degradation kinetics.
  • Potential applications include controlled release and delivery of drugs or proteins as well as cell encapsulation. It can also be used as a delivery vehicle and adhesive for cells in transplantation settings.
  • These innovative hydrogels allow for rapid hydrolytic cleavage in vivo but remain stable in vitro for weeks at neural pH 7 to support regenerative medicine techniques.
9019
Improving Quantitative Phase Imaging to Enhance Reliability and Broaden Applications
  • Universal application of an OBM/qOBM optical phase imaging device is made possible by the optimized SNR that identifies configurations with fewer limitations (e.g., conditions, tissue).
  • The simulated SNR can identify non-intuitive geometries for optical phase imaging devices that previously may not have been identified by the arduous experimental optimization process. 
  • Optimized SNR when OBM/qOBM devices take in-vivo and in-situ measurements have been proven reliable across multiple types of tissue.
8936
Enhanced Diversifying Base Editors for Directed Evolution in S. cerevisiae
  • This invention presents an optimized and integrated CRISPR diversifying base editor for use in yeast and demonstrate its ability to rapidly improve the affinity of an antibody through yeast display. 
  • The innovation has enhanced the base editor mutation rate up has been increased to 27-fold by characterizing an improved key variant and by optimizing the structure of the CRISPR guide RNAs.
  • The technology has attained a rate roughly 10-fold higher than state-of-art systems and facilitates ultra-rapid antibody diversification.
9111
Novel Repressor Proteins for Gene Regulation and CRISPRi
  • The new CRISPRi platform uses novel fusion proteins to specifically inhibit target genes of interest and overcome the off-target issues with existing CRISPR platforms already on the market.
  • The technology can be used as a life science tool and/or for diagnostics and therapeutics.
  • The platform aims to limit off-target editing, circumvent incomplete gene knockdown sgRNA sequence-dependent repression activity, and variable performance across human cancer cell lines.
9106
Enabling Rapid Detection of Label-Free RNA for Use in COVID-19 Testing
  • Earlier detection: Identifying the viral components themselves—rather than the body’s reaction to the viral presence (i.e., antibodies)—potentially improves early detection in asymptomatic subjects.
  • Simpler process: Use of minimal reagents and fewer preparatory steps is designed to enable more efficient and facile sample preparation. Avoidance of “wash steps” aims to minimize target loss.
  • Fewer disruptions: Avoiding the use of high-demand supplies (e.g., swabs) and reagents potentially reduces supply-chain and contamination issues.
8669
Messenger Ribonucleic Acid (mRNA)–Based Opsin Expression Enables New and Safer Optogenetic Studies
  • Opsin expression using messenger RNA (mRNA) provides an alternative to viral vectors for use in optogenetic studies involving neurons as well as drug testing with cardiomyocytes.
  • Expression with mRNAs has lower toxicity and is usually detectable within 2–24 hours rather than 2–3 weeks.
  • The controllable and temporary nature of mRNA offers improved expression regulation based on the transfection amount.
7534
Microfluidic Device Enables Prediction of T-Cell Ability to Home and Engraft to Disease Tissues
  • Improve the homing capabilities of T cells to increase adoptive cell therapy treatment response and safety while decreasing off-target effects.
  • Enhance tumor-infiltrating capabilities with engineered microfluidic devices that identify optimal subsets of cells.
  • Optimize development pipelines by reducing the number of laborious in vivo studies, while also helping cell therapy companies ensure their products reach the desired tissue.
9052
Lymphatic System-Specific Lipid Nanoparticles
  • This platform technology improves current targeting to lymphatic tissues and specifically lymphatic endothelial cells.
  • Provides superior tissue targeting and functional delivery of mRNA to lymphatics via loco-regional dermal or subcutaneous avenues.
  • mRNA-based platforms offer a transient and less immunogenic method of delivery compared to protein therapeutics or adeno-associated virus-based platforms.
9056
Soft Wireless Sternal Patch for Detecting Systemic Vasoconstriction Using Photoplethysmography
  • A wireless, soft sternal patch includes integrated skin-like, photolithographically patterned electronics specifically tuned to continuously measure vasoconstriction from the sternum.
  • In overnight trials, the device detected sleep apnea and hypopnea with 95% precision and 100% sensitivity compared to data professionally scored by licensed clinicians.
  • Use of this patch on the chest could improve detection of key markers of numerous harmful health conditions.
9170